Welcome to our dedicated page for Cvrx news (Ticker: CVRX), a resource for investors and traders seeking the latest updates and insights on Cvrx stock.
CVRx, Inc. (NASDAQ: CVRX) is a commercial-stage medical device company whose news flow centers on its Barostim neuromodulation platform for cardiovascular disease, particularly heart failure. The company regularly issues press releases and investor updates detailing financial performance, operational metrics and developments related to Barostim.
Readers of CVRX news can expect recurring coverage of quarterly and annual financial and operating results, including revenue trends, gross margin, operating expenses, cash and cash equivalents, and the growth of active implanting centers and sales territories in the U.S. and Europe. The company also reports on reimbursement milestones, such as the transition of Barostim procedures to Category I CPT codes and CMS decisions affecting outpatient payment classifications and physician fee levels.
Another key theme in CVRx news is clinical and regulatory progress. The company has highlighted FDA actions such as the Breakthrough Device designation for Barostim and the grant of an Investigational Device Exemption for the BENEFIT-HF trial, a randomized controlled study designed to evaluate Barostim’s impact on outcomes in an expanded heart failure population. Updates on applications to the Centers for Medicare & Medicaid Services for trial coverage and other reimbursement-related developments are also part of the company’s announcements.
CVRx news releases frequently mention participation in major healthcare and investor conferences, where the management team presents the company’s strategy and Barostim-related data to the investment community. For investors and observers following CVRX, this news page provides a centralized view of earnings releases, reimbursement and coding changes, clinical trial plans, financing arrangements, and conference appearances linked to the company’s heart failure therapy platform.
CVRx (NASDAQ: CVRX) announced scientific presentations and late-breaking clinical data on Barostim at THT 2026, March 2-4 in Boston. Key items include six-month outcomes from the REBALANCE Registry in over 400 patients, updates from BREATHE-HF, and initiation of the BENEFIT-HF trial.
The company will host a satellite program March 3, 12:15-1:30 p.m. ET, and said BENEFIT-HF has CMS Category B IDE coverage with enrollment expected to begin in the first half of 2026.
CVRx (NASDAQ: CVRX) reported Q4 2025 revenue of $16.0M (+4% YoY) and full-year 2025 revenue of $56.7M (+10% YoY). Gross margin rose to 85% (FY) and active U.S. implanting centers increased to 252.
The company initiated the BENEFIT-HF randomized trial (2,500 patients, CMS Category B IDE) and amended a term loan to an aggregate facility up to $100M, borrowing an additional $10M (outstanding principal $60M). 2026 revenue guidance: $63.0M–$67.0M.
CVRx (NASDAQ: CVRX) said it will release fourth quarter 2025 financial and operating results after market close on Thursday, February 12, 2026. The company will host a conference call to review results at 4:30 p.m. Eastern Time the same day and provide a live webcast on its investor relations site.
Telephone access is available for U.S. callers at 1-877-704-4453 and international callers at 1-201-389-0920; callers are asked to dial in about ten minutes early.
CVRx (NASDAQ: CVRX) announced initiation of BENEFIT-HF, a randomized trial planned to enroll 2,500 patients across ~150 U.S. and German centers to evaluate Barostim in a significantly expanded heart failure population. The primary endpoint is a composite of all-cause mortality and heart failure decompensation events. Enrollment is expected to begin in the first half of 2026. BENEFIT-HF will test Barostim in patients with LVEF 50% (vs current indication 35%) and NT-proBNP 5,000 pg/mL (vs current 1,600 pg/mL), potentially expanding the indicated population roughly threefold. The trial has CMS Category B IDE coverage to support patient access during the study period.
CVRx (NASDAQ: CVRX) reported preliminary unaudited revenue of approximately $15.9M–$16.1M for Q4 2025 and $56.5M–$56.7M for full year 2025. The company provided 2026 guidance of $63M–$67M total revenue, 84%–86% gross margin and $103M–$107M operating expenses. Category I CPT codes and favorable physician fee payments took effect Jan 1, 2026. FDA granted an IDE for the BENEFIT-HF randomized trial; CMS IDE Category B coverage has been applied for and trial net costs are expected to be $20M–$30M over 5–7 years. The term loan facility was amended to increase capacity to $100M, with $60M outstanding and extended maturity to May 2031. Cash and cash equivalents were $75.7M at Dec 31, 2025.
CVRx (NASDAQ: CVRX) confirmed that Category I CPT codes for baroreflex activation therapy using its Barostim device replaced Category III codes effective Jan 1, 2026. Category I CPT codes indicate an established procedure and can support broader adoption, coverage, and reimbursement across the U.S. healthcare system.
CVRx said U.S. hospitals and physicians should update billing systems and begin using the new codes for procedures performed on or after Jan 1, 2026. The company stated it believes the change will enable more predictable and consistent reimbursement for Barostim patients and providers.
CVRx (NASDAQ: CVRX) announced management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, 2026. The presentation begins at 3:45 p.m. PT and will be available via live webcast at the company's investor site. An archived recording will be posted after the live event and accessible at the same URL for a limited time.
This is a company investor presentation and not an earnings release or regulatory filing.
CVRx (NASDAQ: CVRX) announced its management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, Dec. 3, 2025.
The session is scheduled for 2:00 p.m. ET and will be available via a live audio webcast on the company investor relations website at ir.cvrx.com. The presentation offers investors a chance to hear management discuss recent developments and company outlook.
CVRx (NASDAQ: CVRX) reported third-quarter 2025 results: revenue $14.7M (+10% YoY) with U.S. revenue $13.5M (+10% YoY) and 250 active U.S. implanting centers. Gross profit was $12.8M (+15% YoY) and gross margin 87% (up from 83%). Net loss narrowed slightly to $12.9M (−$0.2M) or $0.49 per share. Cash and cash equivalents totaled $85.1M. CMS finalized Category I CPT coding, which management cites as improving patient access and reducing adoption barriers. Full‑year 2025 guidance was updated to $55.6M–$56.6M revenue, 85%–86% gross margin, and $98M–$99M operating expenses. The company expects Q4 2025 revenue of $15.0M–$16.0M.
CVRx (NASDAQ: CVRX) announced that management will present at the Jefferies Global Healthcare Conference in London on Tuesday, Nov 18, 2025.
The presentation is scheduled for 8:00 a.m. GMT / 4:00 a.m. ET and will be available live via audio webcast on the company investor relations site at ir.cvrx.com.